Editas Medicine, Inc. (EDIT)
$2.27-6.97%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $222M
- Beta
- 2.00
- P/E (TTM)
- -3.04
- Short % float
- 37.97%
- Days to cover
- 9.3
- SI change
- +23.9%
- 1W
- -17.45%
- 1M
- -13.69%
- vs SPY 1W
- -16.47%
- vs SPY 1M
- -15.55%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 22
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-118.0%
REV YoY-
ROE-196.6%
EPS YoY-
ROA-31.2%
GROSS57
OP-175
NET-157
[VALUATION]
P/E TTM-3.04
P/E FWD-
SECTOR PE-
INDUSTRY PE13.99
P/B2.57
P/FCF-
EV/EBITDA-2.60
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E14.73
ALTMAN Z-
CURR RATIO3.19
ND/EBITDA-
BETA2.00
Company news
FAQ
- What is LOPJLB’s current signal on EDIT?
- LOPJLB’s latest quantitative signal on Editas Medicine, Inc. (EDIT) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is EDIT in?
- Editas Medicine, Inc. (EDIT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Editas Medicine, Inc. (EDIT) do?
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. T…